| Literature DB >> 33274929 |
Yuchen Zhou1, Steven Ramsey1, Davide Provasi1, Amal El Daibani2,3, Kevin Appourchaux2,3, Soumen Chakraborty2,3, Abhijeet Kapoor1, Tao Che2,3, Susruta Majumdar2,3, Marta Filizola1.
Abstract
Pain management devoid of serious opioid adverse effects is still far from reach despite vigorous research and development efforts. Alternatives to classical opioids have been sought for years, and mounting reports of individuals finding pain relief with kratom have recently intensified research on this natural product. Although the composition of kratom is complex, the pharmacological characterization of its most abundant alkaloids has drawn attention to three molecules in particular, owing to their demonstrated antinociceptive activity and limited side effects in vivo. These three molecules are mitragynine (MG), its oxidized active metabolite, 7-hydroxymitragynine (7OH), and the indole-to-spiropseudoindoxy rearrangement product of MG known as mitragynine pseudoindoxyl (MP). Although these three alkaloids have been shown to preferentially activate the G protein signaling pathway by binding and allosterically modulating the μ-opioid receptor (MOP), a molecular level understanding of this process is lacking and yet important for the design of improved therapeutics. The molecular dynamics study and experimental validation reported here provide an atomic level description of how MG, 7OH, and MP bind and allosterically modulate the MOP, which can eventually guide structure-based drug design of improved therapeutics.Entities:
Mesh:
Substances:
Year: 2020 PMID: 33274929 PMCID: PMC8119294 DOI: 10.1021/acs.biochem.0c00658
Source DB: PubMed Journal: Biochemistry ISSN: 0006-2960 Impact factor: 3.162